| CAS ID: | 179324-69-7 |
| Molecular Formula: | C19H25BN4O4 |
| Molecular Weight: | 384.3 g/mol |
| Monoisotopic Mass: | 384.1969 g/mol |
| Class: | Small Molecule |
| Natural Product: | No |
| Other Names: | Velcade | LDP-341 | BORTEZOMIB | PS-341 |
| Analysis: | Drug repositioning mechanism analysis |
| InChI: | InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1 | See All |
| InChI Key: | GXJABQQUPOEUTA-RDJZCZTQSA-N | |
| Smiles: | CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O | See All |
| Molfile: | Download |
Reference Record 1
| PubMed ID | 23011081 | Target ID | |
| Uniprot ID | Name | ||
| Model | vitro,rat | Fibrosis Disease | Liver fibrosis |
| Process I | |||
| Process II | HSCs activation,cells apoptosis | ||
| Process III | prevenet collagen deposition | ||
| Mechanism | |||
Reference Record 2
Reference Record 3
| PubMed ID | 21921091 | Target ID | |
| Uniprot ID | Name | ||
| Model | vitro,mice | Fibrosis Disease | Pulmonary fibrosis |
| Process I | |||
| Process II | |||
| Process III | prevenet collagen deposition | ||
| Mechanism | Targeting TGF-β(1) signaling | ||
Reference Record 4
| PubMed ID | 21921091 | Target ID | |
| Uniprot ID | Name | ||
| Model | vitro,mice | Fibrosis Disease | Skin fibrosis |
| Process I | |||
| Process II | |||
| Process III | prevenet collagen deposition | ||
| Mechanism | Targeting TGF-β(1) signaling | ||
Reference Record 5
Trial Record 1
| ClinicalTrial ID | NCT02370693 | Disease | Systemic sclerosis |
| Phase | Phase 2 | Status | Recruiting |
| First Received | February 25, 2015 | Last Verified | March 13, 2019 |
| Sponsor | Northwestern University | ||
| PubChem: | 387447 |
| ChEMBL: | CHEMBL325041 |